Gilead drug ‘works’ against coronavirus: US study


An experimental drug was found effective against coronavirus in a major breakthrough which may potentially be a game-changer as countries around the world fight to contain the amount of new cases and deaths from COVID-19.

US government officials said Wednesday that they would work to make it accessible to appropriate patients as quickly as possible.

In a report on 1,063 patients fortunate enough to be hospitalized, Gilead Sciences’s remdesivir shortened the time to recovery by 31% — 11 times on average versus 15 times for those just given regular care, officials said. The drug also might be reducing deaths, though that’s not sure from the partial results revealed up to now.

“This is going to be the standard of care,” and some other potential treatments will now must be tested against or in combination with remdesivir, he said.

An effective remedy for COVID-19 might have a profound influence on the pandemic’s effect, particularly because a vaccine is very likely to be a year or more away.

Fauci revealed the outcomes while speaking from the White House. Remdesivir was being assessed in at least seven big studies, but this one, led by the NIH, was the strictest test. Independent monitors advised study leaders just days ago that the medication was working, so it was no longer ethical to continue with a placebo group.

Dr. Elizabeth Hohmann, who enrolled 49 patients at the experiment in Massachusetts General Hospital, said study leaders were told Tuesday night that the results derive from”the first cut of 460 patients”

“There is over 1,000 from the study so there is much more information to come” and complete results have to be noticed, she said. “I am cautiously optimistic.”

Dr. Babafemi Taiwo, chief of infectious diseases at Northwestern Medicine, which also participated in the study, called the results”really exciting.”

“For the very first time we have a sizable, well-conducted trial” showing a treatment helps, he said. “This isn’t a miracle drug… but it’s definitely better than anything else we’ve.”

By comparison, antiviral drugs for the flu shorten illness by roughly one day on average and only when started inside a day or 2 of symptoms appearing.

In the remdesivir study, about 8 percent of these on the medication died versus 11.6percent of the comparison group, but the difference isn’t big enough for scientists to state the drug was the motive.

No information was given on negative effects. Fauci said complete results would be published in a health journal soon. He said closing numbers might change a bit but that the study’s overall conclusion wouldn’t.

Remdesivir is one of dozens of treatments being tried against the coronavirus but has been the farthest along in testing. It’s given through an IV and blocks an enzyme that the virus uses to copy its genetic material. In animal tests against SARS and MERS, ailments caused by similar coronaviruses, the drug helped prevent infection and decreased the severity of symptoms when given early enough in the course of disease.

“We are excited and optimistic” about the new effects, stated Vanderbilt University’s Dr. Mark Denison. His lab first analyzed remdesivir contrary to other coronaviruses in 2013 and has done much research on it since, but was not involved in the NIH research.

“It is active against every coronavirus that we’ve ever tested,” Denison said. “It was quite hard for the virus to develop resistance to remdesivir. That means the medication would probably be successful over long term use.”

It quickly enrolled its original goal of 440 patients than was expanded to provide more answers on questions such as which subgroups might or might not gain, along with other aspects that might impact achievement, such as how ancient the medication was granted.

The study only tested the medication in patients ill enough to be hospitalized — normally with pneumonia and often needing oxygen — so its effectiveness and safety for individuals less ill are not known.

The study will continue to enroll new patients. It had been put up as an umbrella trial to examine many treatments, though they now will have to be tested against remdesivir or with it, Fauci said.

Separately on Wednesday, California-based Gilead announced partial results in the own ongoing study of this drug is seriously ill, hospitalized COVID-19 patients. The company said patients treated for five days”achieved similar improvement” in wellness as others treated for 10 days. But that result is hard to interpret because there is not any comparison group of people getting regular care, so it is not possible to understand how much patients would have improved independently.

Still another study analyzed remdesivir in seriously ill patients at China, which was discontinued after just 237 of a planned 453 patients were enrolled. Partial results published Wednesday in the British medical journal Lancet suggest the medication did not speed recovery in that study, but it was too little to be authoritative, Fauci and research leaders stated.

Gilead also is testing remdesivir in a separate analysis of moderately ill coronavirus patients. No results have yet been announced from this study, which will have a contrast set.

Besides the studies, Gilead also has contributed remdesivir to over 1,700 patients onto a case-by-case emergency basis. The drug is not yet approved anywhere in the world for virtually any use.

A statement from the Food and Drug Administration says the bureau was speaking with Gilead” about making remdesivir available to patients as quickly as you can, as appropriate”

Gilead said it had been ramping up production and aims to have over 140,000 treatment classes at the end of May, over 500,000 by October, and more than 1 million from December.

Add Comment